Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Assets (2021 - 2025)

Aligos Therapeutics' Current Assets history spans 5 years, with the latest figure at $82.9 million for Q4 2025.

  • For Q4 2025, Current Assets rose 33.35% year-over-year to $82.9 million; the TTM value through Dec 2025 reached $82.9 million, up 33.35%, while the annual FY2025 figure was $82.9 million, 33.35% up from the prior year.
  • Current Assets reached $82.9 million in Q4 2025 per ALGS's latest filing, down from $103.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $248.7 million in Q3 2021 to a low of $62.1 million in Q4 2024.
  • Average Current Assets over 5 years is $137.6 million, with a median of $130.7 million recorded in 2022.
  • Peak YoY movement for Current Assets: plummeted 55.95% in 2024, then surged 33.35% in 2025.
  • A 5-year view of Current Assets shows it stood at $204.4 million in 2021, then tumbled by 34.67% to $133.5 million in 2022, then increased by 5.65% to $141.1 million in 2023, then crashed by 55.95% to $62.1 million in 2024, then skyrocketed by 33.35% to $82.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Current Assets are $82.9 million (Q4 2025), $103.4 million (Q3 2025), and $127.9 million (Q2 2025).